Retrophin (RTRX) Tops Q4 EPS by 38c, Revenues Beat

Retrophin (NASDAQ: RTRX) reported Q4 EPS of ($0.26), $0.38 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $46.69 million versus the consensus estimate of $46.02 million.

“In 2019 we strengthened our focus through disciplined decisions to move beyond the clinical programs that did not meet our expectations, and we successfully executed on the key strategies to advance our pivotal studies of sparsentan in FSGS and IgA nephropathy,” said Eric Dube, Ph.D., chief executive officer of Retrophin. “With its potential to become the first medicine approved for FSGS and IgA nephropathy, we are seeing growing enthusiasm for sparsentan among the nephrology community and anticipation for the topline readouts from the 36-week proteinuria assessments in DUPLEX and PROTECT. In 2020 we will continue to focus on completing enrollment and maintaining high quality trial conduct in these two pivotal studies, while simultaneously preparing for regulatory submissions for the programs. Further, we will continue to focus on building upon our existing commercial capabilities in order to support the continued organic growth of our approved products, and ultimately maximizing sparsentan’s potential for patients.”

For earnings history and earnings-related data on Retrophin (RTRX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Pulmatrix (PULM) Reports Q2 Loss of $0.29
• Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c